Former President and CEO
Abigail Jenkins has over 20 years of leadership experience in large and small biotech and pharmaceutical companies, focused on commercialization and corporate strategy. Abigail currently serves on the boards of Aquestive Therapeutics and XORTX Therapeutics. She most recently served as president, CEO and board member of Gamida Cell, where she oversaw the FDA approval of the company’s groundbreaking allogeneic hematopoietic stem cell donor source Omisirge. Prior to Gamida Cell, Abigail served as the chief commercial and business officer at Lyndra Therapeutics, where she led portfolio management across multiple therapeutic areas. Prior to Lyndra Therapeutics, she served as SVP and business unit head of vaccines at Emergent BioSolutions, where she oversaw the company’s largest therapeutic division from discovery through commercialization. Abigail previously served as chief commercial officer and U.S. business head at Aquinox Pharmaceuticals in addition to holding senior positions at Relypsa, Actavis, Pfizer and Medimmune. Abigail holds an M.S. from Johns Hopkins University and a B.A. from Indiana University. She was recognized in 2022 as one of the PharmaVoice 100.